# US 2016/0257939 A1 · Reprogramming t cells and hematopoietic cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257939 A1
- Document ID: US20160257939A1
- Status: Published application
- Kind: A1
- Application number: 15/139,746
- Filed: 2016-04-27
- Published: 2016-09-08
- Earliest claimed: 2009-06-05
- Assignees: Cellular Dynamics International, Inc.
- Applicants: Cellular Dynamics International, Inc.
- Inventors: Matthew BROWN; Elizabeth Rondon DOMINGUEZ; Randy LEARISH; Emile NUWAYSIR; Deepika RAJESH; Amanda MACK
- Web page: https://patentgrep.com/patent/US20160257939A1

## CPC

- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- C12N 5/0637: {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- C12N 15/85: for animal cells
- C12N 15/86: Viral vectors
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2501/602: Sox-2
- C12N 2501/603: Oct-3/4
- C12N 2501/604: Klf-4
- C12N 2501/605: Nanog
- C12N 2501/606: c-Myc
- C12N 2501/608: Lin28
- C12N 2502/1114: T cells
- C12N 2506/11: from blood or immune system cells
- C12N 2510/00: Genetically modified cells
- C12N 2740/10043: viral genome or elements thereof as genetic vector
- C12N 2800/108: episomal vectors
- C12N 2830/20: transcription of more than one cistron
- Y02E 60/10: Energy storage using batteries
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02E: REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION

## Abstract

Methods and compositions relating to the production of induced pluripotent stem cells (iPS cells) are disclosed. For example, induced pluripotent stem cells may be generated from CD34+ hematopoietic cells, such as human CD34+blood progenitor cells, or T cells. Various iPS cell lines are also provided. In certain embodiments, the invention provides novel induced pluripotent stem cells with a genome comprising genetic rearrangement of T cell receptors.

## Claims

### Claim 1

A method for producing induced pluripotent stem cells from T cells or CD34+ hematopoietic progenitor cells comprising the steps of:
(a) obtaining a cell population comprising T cells or CD34+ hematopoietic progenitor cells, wherein the CD34+ hematopoietic progenitor cells are from a subject whose cells have not been mobilized with extrinsically applied granulocyte colony-stimulating factor (G-CSF); and
(b) producing iPS cells from the T cells or CD34+ hematopoietic progenitor cells of the cell population through the introduction of nucleic acids encoding reprogramming factors comprised in one or more viral vectors, and culturing the cells under defined, feeder-free conditions to provide an iPS cell population.

### Claim 2 (depends on 1)

The method of claim 1, wherein the source of the cell population is a blood sample, blood components, bone marrow, lymph node, fetal liver, or umbilical cord.

### Claim 3 (depends on 2)

The method of claim 2, wherein the source of the cell population is a blood sample of from about 1 to about 5 ml.

### Claim 4 (depends on 3)

The method of claim 3, wherein the source of the cell population is a blood sample of about 3 ml.

### Claim 5 (depends on 1)

The method of claim 1, wherein the source of the cell population comprising T cells is a subject whose cells have not been mobilized with extrinsically applied G-CSF.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cell population has been cryopreserved.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cell population comprising T cells is prepared in vitro or in vivo under conditions that will activate the T cells.

### Claim 8 (depends on 7)

The method of claim 7, wherein a cell population comprising T cells is cultured in the presence of an anti-CD3 antibody.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cell population comprising T cells or CD34+ hematopoietic progenitor cells is cultured in vitro with one or more cytokines to expand the T cell or CD34+ hematopoietic progenitor cells population therein.

### Claim 10 (depends on 9)

The method of claim 9, wherein the cell population comprises T cells, and wherein the one or more cytokines comprises IL-2.

### Claim 11 (depends on 9)

The method of claim 9, wherein the cell population comprises CD34+ hematopoietic progenitor cells, and wherein the one or more cytokines comprises at least one of SCF, Flt3L, or IL-3.

### Claim 12 (depends on 1)

The method of claim 1, wherein the T cells are human T cells.

### Claim 13 (depends on 1)

The method of claim 1, wherein the CD34+ hematopoietic progenitor cells are human CD34+ hematopoietic progenitor cells.

### Claim 14 (depends on 1)

The method of claim 1, wherein the T cells are CD4+ or CD8+ T cells.

### Claim 15 (depends on 1)

The method of claim 1, wherein the T cells are T helper 1 (TH1) cells, T helper 2 (TH2) cells, TH17 cells, cytotoxic T cells, regulatory T cells, natural killer T cells, naïve T cells, memory T cells, or gamma delta T cells.

### Claim 16 (depends on 1)

The method of claim 1, wherein the cell population comprises from about 90% to about 99% T cells.

### Claim 17 (depends on 1)

The method of claim 1, wherein the cell population comprises from about 97% to about 99% T cells.

### Claim 18 (depends on 1)

The method of claim 1, wherein the cell population comprises at least 1×103 T cells.

### Claim 19 (depends on 1)

The method of claim 1, wherein the cell population comprises at least 5×103 T cells.

### Claim 20 (depends on 1)

The method of claim 1, wherein the cell population comprises from about 1×106 to about 2×106 T cells.

### Claim at position 21

-23. (canceled)

### Claim 24 (depends on 1)

The method of claim 1, wherein the reprogramming factors are encoded by one or more expression cassettes and comprise a Sox family protein and an Oct family protein.

### Claim 25 (depends on 24)

The method of claim 24, wherein the one or more expression cassettes comprise at least a polycistronic transcript unit.

### Claim 26 (depends on 25)

The method of claim 25, wherein the polycistronic transcript unit comprises at least two reprogramming genes.

### Claim 27 (depends on 26)

The method of claim 26, wherein the polycistronic transcript unit comprises a Sox gene and an Oct gene.

### Claim 28 (depends on 26)

The method of claim 26, wherein the polycistronic transcript unit comprises a cMyc gene and a Klf4 gene.

### Claim 29 (depends on 26)

The method of claim 26, wherein the polycistronic transcript unit comprises a Nanog gene and an Lin28 gene.

### Claim 30 (depends on 25)

The method of claim 25, wherein the polycistronic transcript unit comprises a reprogramming gene and a selectable or screenable marker.

### Claim 31 (depends on 25)

The method of claim 25, wherein the polycistronic transcription unit comprises an internal ribosome entry site (IRES) or a sequence coding for at least one protease cleavage site and/or self-cleaving peptide for polycistronic transcription.

### Claim 32

(canceled)

### Claim 33 (depends on 1)

The method of claim 1, wherein the reprogramming vector is a retroviral vector.

### Claim 34 (depends on 24)

The method of claim 24, wherein the Sox family protein is Sox2.

### Claim 35 (depends on 24)

The method of claim 24, wherein the Oct family protein is Oct4.

### Claim 36 (depends on 24)

The method of claim 24, wherein the reprogramming proteins further comprise Nanog, Lin28, c-Myc, Klf4, or Esrrb.

### Claim 37 (depends on 36)

The method of claim 36, wherein the reprogramming proteins further comprise Nanog.

### Claim 38 (depends on 36)

The method of claim 36, wherein the reprogramming proteins further comprise Klf4 and c-Myc.

### Claim 39 (depends on 1)

The method of claim 1, wherein producing iPS cells from the T cells or CD34+ hematopoietic progenitor cells of the population further comprises selecting the iPS cells for one or more characteristics of embryonic stem cells.

### Claim 40 (depends on 39)

The method of claim 39, wherein the characteristic is an adherent property, an undifferentiated morphology, an embryonic stem cell-specific marker or pluripotency.

### Claim 41 (depends on 40)

The method of claim 40, wherein the characteristic is an adherent property.

### Claim 42 (depends on 40)

The method of claim 40, wherein the characteristic is an undifferentiated morphology.

### Claim 43 (depends on 1)

The method of claim 1, wherein the method further comprises differentiating the iPS cells to a differentiated cell.

### Claim 44 (depends on 43)

The method of claim 43, wherein the differentiated cell comprises a cardiomyocyte, a hematopoietic cell, a neuron, a fibroblast or an epidermal cell.

### Claim 45 (depends on 1)

The method of claim 1, wherein the iPS cell population is essentially free of integrated, exogenous viral elements.

### Claim at position 44

-49. (canceled)
